Based on its receptor status, breast cancer is traditionally categorized as ER-positive, PgR-positive, HER2-positive, or triple-negative (ER-negative, PgR-negative, HER2-negative) (TNBC). This evidence concerns the gene ERBB2 and breast carcinoma.